News | Cardio-oncology | September 28, 2016

Cardiac Risk a Factor When Considering Hormonal Therapy for Prostate Cancer

Decision analysis model study shows men with low-risk prostate cancer and history of heart attack may be harmed by adding hormone therapy to radiation therapy

prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016

September 28, 2016 — In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented at the American Society for Radiation Oncology (ASTRO) meeting, Sept. 25-28 in Boston.

Hormone therapy is used for treatment of prostate cancer to block the production of androgens, or male sex hormones. Androgens are necessary for the growth and spread of prostate cancer cells. Hormone therapy suppresses the androgen production in the body and stops the spread and growth of prostate cancer cells.

This study used a previously published decision analysis model that compared quality-adjusted life years (QALYs) in men aged 50, 60 and 70 years who received radiation therapy and no hormone therapy for high-risk prostate cancer and their cardiac risk factors. The research team used data from the recently published EORTC 22991 trial to study men with intermediate-risk prostate cancer, randomized to either radiation therapy or radiation therapy and six months of hormone therapy.

Hormone therapy was associated with a net decrease of 0.3 – 0.4 QALYs in men with a prior history of heart attack. However, for all other men, hormone therapy improved QALYs (range 0.4 - 2.6). Younger men with fewer cardiac risk factors experienced the largest benefit from hormone therapy. Men at low risk for biochemical failure (≤8.7 percent at 5 years) did not benefit from hormone therapy. Further, the benefits of hormone therapy did not begin to manifest until after 7.3 years of follow-up.

“Patient age, cardiac risk, and disease recurrence risk should be considered when selecting candidates for hormone therapy in this patient population,” said Nataniel Lester-Coll, M.D., first author on the study and a resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Men with a history of heart attack who are at very low risk for biochemical failure may be harmed by the addition of hormone therapy.”

For more information: www.astro.org

Related Content

CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
ACC Hosts Third Annual Cardio-Oncology Course
News | Cardio-oncology | January 28, 2019
The American College of Cardiology host the third Advancing the Cardiovascular Care of the Oncology Patient course in...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Heart Attack, Stroke Risks Increase Leading Up to Cancer Diagnosis
News | Cardio-oncology | December 21, 2018
Older adults with cancer are more likely to have had a heart attack or stroke in the months prior to their cancer...
Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
News | Cardio-oncology | December 07, 2018
New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE, or blood clot)...
Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage
News | Cardio-oncology | March 14, 2018
After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to...
Heart Failure More Likely for Some Breast Cancer and Lymphoma Survivors
News | Cardio-oncology | March 01, 2018
March 1, 2018 –  Patients who were treated for breast cancer or lymphoma are more than three times at risk for develo
Overlay Init